| Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy. | None |
| This review addresses the physiological function of wild-type Vav1, its mode of activation as an oncogene, and its emerging role as a transforming protein in human cancer. | None |
| Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. | None |
| The oncogenic truncation of this region elicits conformational changes that interfere with the Vav1-mediated activation of PLCgamma1 and that inhibit calcium mobilization. | None |
| vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. | None |
| Data indicate that only a single mutation in the proto-oncogene Vav1 enhances tumorigenicity. | None |
| These findings establish VAV1 as a critical epigenetically regulated oncogene with a key role in MBSHH maintenance, and highlight its potential as a validated therapeutic target and prognostic biomarker for the improved therapy of medulloblastoma. | None |
| These results support a driver oncogenic role for VAV1 signaling in the pathogenesis of PTCL. | None |
| The proto-oncogene Vav product is constitutively tyrosine-phosphorylated in normal human immature T cells. | None |
| Interferon alpha induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopoietic cells. | None |
| Interleukin-2 induces tyrosine phosphorylation of the vav proto-oncogene product in human T cells: lack of requirement for the tyrosine kinase lck. | None |
| Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. | None |
| The vav proto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro. | None |
| Association of the vav proto-oncogene product with poly(rC)-specific RNA-binding proteins. | None |
| Interactions between the protein-tyrosine kinase ZAP-70, the proto-oncoprotein Vav, and tubulin in Jurkat T cells. | None |
| Expression of vav proto-oncogene by nonhematopoietic trophoblast cells at the human uteroplacental interface. | None |
| Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product. | None |
| SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin. | None |
| Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product. | None |
| Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. | None |